retatrutide nejm 2023 obesity trial ly3437943 just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric Today, we shared new data

Retatrutide is a once-weekly injectable medication being studied for significant weight loss

The pattern: blockbusters now cycle faster: shorter dominance windows, steeper cliffs, quicker replacements

Disproportionate fatigue is another signal

High accuracy for better decision-making The Dexcom G7 15 Day sensor is designed to provide users with highly accurate glucose readings

We understand the nuances of managing medications like Zepbound, and our team is always ready to address your concerns, from storage during travel to adjusting your dosage schedule across time zones

Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies